{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:14:04Z","timestamp":1793459644742,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22fk0108509"],"award-info":[{"award-number":["JP22fk0108509"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jiac.2024.01.008","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T21:46:00Z","timestamp":1705527960000},"page":"793-795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir\/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0623-214X","authenticated-orcid":false,"given":"Taketomo","family":"Maruki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-020X","authenticated-orcid":false,"given":"Kiyoko","family":"Iwatsuki-Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-5157","authenticated-orcid":false,"given":"Seiya","family":"Yamayoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Ohmagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jiac.2024.01.008_bib1","doi-asserted-by":"crossref","first-page":"ofab217","DOI":"10.1093\/ofid\/ofab217","article-title":"The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient\u2014a case study","volume":"8","author":"Sepulcri","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2024.01.008_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/2159-8290.CD-21-1033","article-title":"Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies","volume":"12","author":"Lee","year":"2022","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.jiac.2024.01.008_bib3","doi-asserted-by":"crossref","first-page":"ofac382","DOI":"10.1093\/ofid\/ofac382","article-title":"Extended remdesivir infusion for persistent coronavirus disease 2019 infection","volume":"9","author":"Martinez","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"10.1016\/j.jiac.2024.01.008_bib4","doi-asserted-by":"crossref","first-page":"ofad306","DOI":"10.1093\/ofid\/ofad306","article-title":"Successful treatment of persistent symptomatic coronavirus disease 19 infection with extended-duration Nirmatrelvir-Ritonavir among outpatients with hematologic cancer","volume":"10","author":"Liu","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.jiac.2024.01.008_bib5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/23744235.2023.2223274","article-title":"Successful treatment of persisting SARS-CoV-2 infection in an immunocompromised patient with repeated nirmatrelvir\/ritonavir courses: a case report","volume":"55","author":"Lindahl","year":"2023","journal-title":"Inf Disp"},{"issue":"5","key":"10.1016\/j.jiac.2024.01.008_bib6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/cid\/ciac847","article-title":"Dual antiviral therapy for persistent coronavirus disease 2019 and associated organizing pneumonia in an immunocompromised Host","volume":"76","author":"Trottier","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.01.008_bib7","article-title":"Case report: sotrovimab, remdesivir and nirmatrelvir\/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19","volume":"9","author":"Baldi","year":"2022","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.jiac.2024.01.008_bib8","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/cid\/ciad085","article-title":"Successful combination treatment for persistent severe acute respiratory syndrome coronavirus 2 infection","volume":"76","author":"Blennow","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2024.01.008_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/cid\/ciad181","article-title":"Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients","volume":"77","author":"Mikulska","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"10324","key":"10.1016\/j.jiac.2024.01.008_bib10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0140-6736(22)00101-5","article-title":"Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial","volume":"399","author":"Polizzotto","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jiac.2024.01.008_bib11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/infdis\/jiad178","article-title":"Changes in anti-SARS-CoV-2 antibody titers of pooled plasma derived from donors in Japan: a potential tool for mass-immunity evaluation","volume":"228","author":"Yunoki","year":"2023","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2024.01.008_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/trf.16161","article-title":"Neutralizing and binding activities against SARS-CoV-1\/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan","volume":"61","author":"Kubota-Koketsu","year":"2021","journal-title":"Transfusion"},{"issue":"5","key":"10.1016\/j.jiac.2024.01.008_bib13","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ccell.2023.04.005","article-title":"Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer","volume":"41","author":"Wu","year":"2023","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.jiac.2024.01.008_bib14","first-page":"664","article-title":"Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients","volume":"4","author":"Bruel","year":"2023","journal-title":"M\u00e9d"},{"key":"10.1016\/j.jiac.2024.01.008_bib15","volume":"A1","year":"2023"},{"key":"10.1016\/j.jiac.2024.01.008_bib16","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.jiac.2024.01.008_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.jiac.2024.01.008_bib18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Yusof","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.jiac.2024.01.008_bib19","article-title":"COVID-19 virus infection in three patients with hypogammaglobulinemia","volume":"13","author":"Gesiotto","year":"2021","journal-title":"Cureus"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T19:46:27Z","timestamp":1731181587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1341321X24000126"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.01.008","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir\/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}